EBioMedicine (Jul 2020)

Extremely low viral reservoir in treated chronically HIV-1-infected individuals

  • Cristina Gálvez,
  • Victor Urrea,
  • Judith Dalmau,
  • Montse Jimenez,
  • Bonaventura Clotet,
  • Valérie Monceaux,
  • Nicolas Huot,
  • Lorna Leal,
  • Victoria González-Soler,
  • Maria González-Cao,
  • Michaela Müller-Trutwin,
  • Asier Sáez-Cirión,
  • Felipe García,
  • Julià Blanco,
  • Javier Martinez-Picado,
  • Maria Salgado

Journal volume & issue
Vol. 57
p. 102830

Abstract

Read online

Background: Small viral reservoirs are found predominantly in HIV-1 controllers and individuals treated during acute/early HIV-1 infection. However, other HIV+ individuals could naturally also harbour low viral reservoirs. Methods: We screened 451 HIV-1-infected treated-individuals with suppressed plasma viremia for at least 3 years and stored cryopreserved peripheral blood mononuclear cells (PBMCs). Total HIV-DNA was analysed in PBMCs with ddPCR. Individuals with 50 HIV-DNA copies/106 PBMCs) to analyse total HIV-DNA, T-cell and NK-cell populations, HIV-1 specific antibodies, and plasma inflammation markers. Findings: We found that 9.3% of the individuals screened had <50 HIV-DNA copies/106 PBMCs. At least 66% initiated cART during the chronic phase of HIV-1 infection (cp-LoViReT). Cp-LoViReT harboured lower levels of HIV-DNA before cART and after treatment introduction the decays were greater compared to controls. They displayed a marked decline in quantity and avidity in HIV-specific antibodies after initiation of cART. Cp-LoViReT had fewer CD8+ TTM and TEMRA in the absence of cART, and higher CD8+ TN after 18 months on therapy. Interpretation: Treated chronically HIV-1-infected LoViReT represent a new phenotype of individuals characterized by an intrinsically reduced viral reservoir, less impaired CD8+ T-cell compartment before cART, and low circulating HIV-1 antigens despite being treated in the chronic phase of infection. The identification of this unique group of individuals is of great interest for the design of future eradication studies. Funding: MSD Spain

Keywords